Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
sarepta therapeutics将会上涨约30%?以下是周四的10位顶尖分析师预测
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
华尔街顶级分析师改变了对这些知名人士的看法。要全面了解所有分析师评级变动,包括上调和降级,请参阅我们的分析师评级页面。
- Piper Sandler boosted Duolingo, Inc. (NASDAQ:DUOL) price target from $271 to $351. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Duolingo shares closed at $318.85 on Wednesday. See how other analysts view this stock.
- B of A Securities cut the price target for Bloom Energy Corporation (NYSE:BE) from $8 to $7. B of A Securities analyst Julien Dumoulin-Smith maintained an Underperform rating. Bloom Energy shares closed at $10.97 on Wednesday. See how other analysts view this stock.
- Needham raised the price target for Vertex, Inc. (NASDAQ:VERX) from $45 to $60. Needham analyst Joshua Reilly maintained a Buy rating. Vertex shares closed at $49.76 on Wednesday. See how other analysts view this stock.
- Baird increased McKesson Corporation (NYSE:MCK) price target from $531 to $688. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. McKesson shares settled at $549.31 on Wednesday. See how other analysts view this stock.
- TD Cowen raised Dutch Bros Inc. (NYSE:BROS) price target from $47 to $53. TD Cowen analyst Andrew Charles maintained a Buy rating. Dutch Bros shares closed at $34.94 on Wednesday. See how other analysts view this stock.
- Truist Securities cut Devon Energy Corporation (NYSE:DVN) price target from $49 to $43. Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold. Devon Energy shares closed at $40.02 on Wednesday. See how other analysts view this stock.
- Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to Overweight. Sarepta shares settled at $127.97 on Wednesday. See how other analysts view this stock.
- Leerink Partners raised Zymeworks Inc. (NASDAQ:ZYME) price target from $10 to $25. Leerink Partners analyst Andrew Berens upgraded the stock from Market Perform to Outperform. Zymeworks shares closed at $15.61 on Wednesday. See how other analysts view this stock.
- Loop Capital slashed the price target for Crocs, Inc. (NYSE:CROX) from $150 to $110. Loop Capital analyst Laura Champine downgraded the stock from Buy to Hold. Crocs shares closed at $102.74 on Wednesday. See how other analysts view this stock.
- Keefe, Bruyette & Woods increased Lemonade, Inc. (NYSE:LMND) price target from $18 to $21. Keefe, Bruyette & Woods analyst Thomas McJoynt-Griffith downgraded the stock from Market Perform to Underperform. Lemonade shares closed at $29.29 on Wednesday. See how other analysts view this stock.
- 派珀·桑德勒将Duolingo, Inc.(纳斯达克股票代码:DUOL)的目标股价从271美元上调至351美元。派珀·桑德勒分析师阿文德·拉姆纳尼维持增持评级。周三,Duolingo股价收于318.85美元。看看其他分析师如何看待这只股票。
- b的A证券将布卢姆能源公司(纽约证券交易所代码:BE)的目标股价从8美元下调至7美元。b的A证券分析师朱利恩·杜穆林-史密斯维持了表现不佳的评级。布鲁姆能源股价周三收于10.97美元。看看其他分析师如何看待这只股票。
- 尼德姆将Vertex, Inc.(纳斯达克股票代码:VERX)的目标股价从45美元上调至60美元。尼德姆分析师约书亚·赖利维持买入评级。Vertex股价周三收于49.76美元。看看其他分析师如何看待这只股票。
- 贝尔德将麦克森公司(纽约证券交易所代码:MCK)的目标股价从531美元上调至688美元。贝尔德分析师埃里克·科德威尔将该股从中性上调至跑赢大盘。麦克森股价周三收于549.31美元。看看其他分析师如何看待这只股票。
- 道明考恩将荷兰兄弟公司(纽约证券交易所代码:BROS)的目标股价从47美元上调至53美元。道明考恩分析师安德鲁查尔斯维持买入评级。荷兰兄弟股价周三收于34.94美元。看看其他分析师如何看待这只股票。
- Truist Securities将德文能源公司(纽约证券交易所代码:DVN)的目标股价从49美元下调至43美元。Truist Securities分析师尼尔·丁曼将该股的评级从买入下调至持有。德文能源股价周三收于40.02美元。看看其他分析师如何看待这只股票。
- 坎托·菲茨杰拉德将萨雷普塔疗法公司(纳斯达克股票代码:SRPT)的目标股价从152美元上调至167美元。坎托·菲茨杰拉德分析师克里斯汀·克鲁斯卡将该股从中性上调至增持。周三,萨雷普塔股价收于127.97美元。看看其他分析师如何看待这只股票。
- Leerink Partners将Zymeworks Inc.(纳斯达克股票代码:ZYME)的目标股价从10美元上调至25美元。Leerink Partners分析师安德鲁·贝伦斯将该股从市场表现上调至跑赢大盘。Zymeworks股价周三收于15.61美元。看看其他分析师如何看待这只股票。
- Loop Capital将Crocs, Inc.(纽约证券交易所代码:CROX)的目标股价从150美元下调至110美元。Loop Capital分析师劳拉·尚平将该股的评级从买入下调至持有。Crocs股价周三收于102.74美元。看看其他分析师如何看待这只股票。
- Keefe、Bruyette & Woods将Lemonade, Inc.(纽约证券交易所代码:LMND)的目标股价从18美元上调至21美元。Keefe、Bruyette & Woods分析师托马斯·麦乔因-格里菲斯将该股的评级从市场表现下调至表现不佳。Lemonade股价周三收于29.29美元。看看其他分析师如何看待这只股票。
Read More:
阅读更多:
- Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
- 吉姆·克莱默:像博通一样,这只金融股值得买入